CV Lattes
ResearcherID
ORCID
Secretaria da Saúde (São Paulo - Estado). Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da USP (HCMRP). Hemocentro de Ribeirão Preto (Institutional affiliation from the last research proposal) Birthplace: Brazil
Sarah Caroline Gomes de Lima in research grants and scholarships supported by FAPESP.
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Despite the remarkable clinical results, the autologous nature of CAR-T cell manufacturing process restricts the access of patients to this therapy. Therefore, one of the next frontiers in the field is to develop an allogeneic, 'off-the-shelf', CAR-T cell therapy. Initial studies have already provided a proof-of-concept of such "universal" therapy by knocking out the T cell receptor (TCR)…
Glioblastoma (GBM) is an aggressive tumor with a discouraging prognosis. The main chemotherapy protocol includes the alkylating agent temozolomide (TMZ). DNA repair pathways, as the one mediated by the MGMT (O6-methylguanine-DNA methyltransferase) enzyme and the Base Excision Repair (BER), promote resistance to base lesions induced by TMZ, constituting a major obstacle to reach therapeuti…
The use of autologous T cells expressing chimeric antigen receptors (CAR) has revolutionized the therapy of B-cell neoplasms. However, the use of allogeneic CAR-T cells has numerous advantages over this autologous approach, such as the immediate availability of cryopreserved batches for infusion, standardization of the final cell product, time for multiple genetic modifications in cells, …
| 2 / 2 | Completed scholarships in Brazil |
| 1 / 1 | Completed scholarships abroad |
| 3 / 3 | All Scholarships |
| Associated processes | |